pluristem
ceo
issues
shareholder
update
haifa
israel
globe
newswire
pluristem
therapeutics
nasdaq
psti
tase
psti
leading
regenerative
medicine
company
developing
platform
novel
biological
products
today
issued
update
shareholders
chief
executive
officer
president
yaky
yanay
dear
fellow
shareholders
year
saw
unprecedented
need
collaboration
industry
government
order
meet
challenge
pandemic
pluristem
fully
engaged
effort
harnessing
knowledge
experience
dedication
improve
wellbeing
patients
believe
regenerative
medicine
product
candidates
ideally
suited
today
healthcare
challenges
late
stage
pipeline
product
candidates
indications
paving
way
towards
marketing
commercialization
strengthening
global
presence
strategic
collaborations
including
recent
one
abu
dhabi
stem
cells
center
reported
july
heading
pivotal
year
four
clinical
readouts
expected
including
interim
analysis
phase
iii
study
critical
limb
ischemia
cli
top
line
efficacy
results
phase
iii
study
muscle
regeneration
following
hip
fracture
top
line
efficacy
results
phase
ii
study
data
analysis
phase
study
incomplete
hematopoietic
recovery
following
hematopoietic
cell
transplantation
hct
phase
iii
cli
study
interim
data
analysis
fourth
quarter
calendar
expect
announce
interim
analysis
results
global
pivotal
phase
iii
study
cli
continue
enroll
patients
full
clinical
study
europe
israel
recently
added
clinical
sites
part
efforts
introduce
plx
cells
additional
key
medical
centers
interim
final
data
set
results
expected
enable
discussions
food
drug
administration
fda
european
medicines
agency
ema
regarding
filing
biologics
license
application
bla
phase
ii
study
past
weeks
shifted
clinical
site
openings
new
york
area
regions
follow
spread
pandemic
also
considering
adding
clinical
partners
accelerate
site
openings
line
steps
updating
expectation
completing
enrollment
first
quarter
calendar
year
expanded
access
program
patients
suffering
severe
complicated
acute
respiratory
distress
syndrome
ards
eligible
inclusion
phase
ii
study
may
treated
gathered
data
evaluated
alongside
phase
ii
study
data
europe
continue
advance
phase
ii
clinical
study
cleared
germany
commence
patient
enrollment
israel
continue
treat
patients
compassionate
use
program
financial
update
pluristem
million
cash
cash
equivalents
bank
deposits
june
moving
forward
fiscal
year
coincides
jewish
new
year
reiterate
pluristem
commitment
stakeholders
including
shareholders
patients
employees
partners
year
brought
unprecedented
challenges
witnessed
ever
pluristem
resilience
ability
face
challenges
credit
dedicated
passionate
employees
profound
commitment
excellence
proud
tenured
team
employees
company
years
truly
believe
strong
culture
one
reason
pluristem
recognition
one
best
places
work
israel
four
years
row
importantly
see
commitment
employees
one
main
factors
driving
success
committed
continuing
drive
success
coming
year
sincerely
yaky
yanay
chief
executive
officer
pluristem
therapeutics
pluristem
therapeutics
leading
regenerative
medicine
company
developing
novel
cell
therapy
product
candidates
company
reported
robust
clinical
trial
data
multiple
indications
patented
plx
cell
product
candidates
currently
conducting
late
stage
clinical
trials
several
indications
plx
cell
product
candidates
believed
release
range
therapeutic
proteins
response
inflammation
ischemia
muscle
trauma
hematological
disorders
radiation
damage
cells
grown
using
company
proprietary
expansion
technology
administered
patients
without
tissue
matching
pluristem
strong
intellectual
property
position
operated
manufacturing
research
facility
strategic
relationships
major
research
institutions
seasoned
management
team
safe
harbor
statement
press
release
contains
express
implied
statements
within
private
securities
litigation
reform
act
federal
securities
laws
example
pluristem
using
statements
discusses
belief
regenerative
medicine
product
candidates
ideally
suited
today
healthcare
challenges
belief
heading
pivotal
year
four
clinical
readouts
expected
including
interim
analysis
phase
iii
study
cli
top
line
efficacy
results
phase
iii
study
muscle
regeneration
following
hip
fracture
top
line
efficacy
results
phase
ii
study
data
analysis
phase
study
incomplete
hematopoietic
recovery
following
hct
expects
interim
final
data
set
results
phase
iii
cli
study
enable
discussions
fda
ema
regarding
filing
bla
expects
complete
enrollment
phase
ii
study
first
quarter
calendar
year
belief
strong
culture
one
reason
recognition
one
best
places
work
israel
four
years
row
statements
implications
based
current
expectations
management
pluristem
subject
number
factors
uncertainties
could
cause
actual
results
differ
materially
described
statements
following
factors
among
others
could
cause
actual
results
differ
materially
described
statements
changes
technology
market
requirements
pluristem
may
encounter
delays
obstacles
launching
successfully
completing
clinical
trials
pluristem
products
may
approved
regulatory
agencies
pluristem
technology
may
validated
progresses
methods
may
accepted
scientific
community
pluristem
may
unable
retain
attract
key
employees
whose
knowledge
essential
development
products
unforeseen
scientific
difficulties
may
develop
pluristem
process
pluristem
products
may
wind
expensive
anticipates
results
laboratory
may
translate
equally
good
results
real
clinical
settings
results
preclinical
studies
may
correlate
results
human
clinical
trials
pluristem
patents
may
sufficient
pluristem
products
may
harm
recipients
changes
legislation
may
adversely
impact
pluristem
inability
timely
develop
introduce
new
technologies
products
applications
loss
market
share
pressure
pricing
resulting
competition
could
cause
actual
results
performance
pluristem
differ
materially
contemplated
statements
except
otherwise
required
law
pluristem
undertakes
obligation
publicly
release
revisions
statements
reflect
events
circumstances
date
hereof
reflect
occurrence
unanticipated
events
detailed
description
risks
uncertainties
affecting
pluristem
reference
made
pluristem
reports
filed
time
time
securities
exchange
commission
contact
dana
rubin
director
investor
relations
danar
